EVALUATION OF IMMUNOGENICITY AND SAFETY OF GENEVAC B: A NEW RECOMBINANT HEPATITIS B VACCINE IN COMPARISON WITH ENGERIX B AND SHANVAC B IN HEALTHY ADULTS
- 1 January 2004
- journal article
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 22 (1) , 34-38
- https://doi.org/10.1016/s0255-0857(21)02948-0
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Seroepidemiology of Hepatitis B Virus Infection in ChildrenJAMA, 1996
- Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adultsVaccine, 1995
- Development and production aspects of a recombinant yeast-derived hepatitis B vaccineVaccine, 1990
- Hepatitis B: global importance and need for controlVaccine, 1990
- Summary of safety and efficacy data on a yeast-derived hepatitis B vaccineThe American Journal of Medicine, 1989
- Clinical experience with hepatitis B vaccinesAmerican Journal of Infection Control, 1989
- Production and immunological analysis of recombinant hepatitis B vaccineJournal of Infection, 1986